Odyssey Health Inc.

Odyssey Health, Inc. (OTC: ODYY) is a clinical-stage pharmaceutical company developing TM6 — a proprietary formulation of a naturally occurring compound — as a treatment for mild traumatic brain injury (mTBI), including sports-related concussions, which affect millions of athletes, military personnel, and accident victims annually and for which no FDA-approved pharmacological treatment currently exists. According to its website at odysseyhealth.com, the company's TM6 development program is designed to address the significant unmet medical need for effective pharmacological intervention in the acute management of concussion, where current standard of care consists primarily of rest and symptom management without any approved drug treatment that addresses the neurobiological pathways involved in concussion injury and recovery. TM6's mechanism of action targets key aspects of the neuroinflammatory response that drives ongoing injury and impaired recovery following concussive brain trauma.

Odyssey Health's TM6 development program, described at odysseyhealth.com, advances the compound through preclinical and clinical development stages designed to demonstrate its safety and efficacy in acute concussion management, building toward an FDA approval pathway for TM6 as the first pharmacological treatment specifically indicated for mild traumatic brain injury. The company's development strategy includes animal model studies demonstrating TM6's biological activity in concussion models, safety pharmacology and toxicology studies required to support human clinical trials, and IND-enabling studies that form the preclinical package required for FDA authorization to begin human clinical investigation of TM6 in concussion patients. Odyssey Health's clinical development focus on concussion is informed by the growing scientific understanding of the neuroinflammatory, excitotoxic, and metabolic mechanisms that contribute to concussion symptom burden and recovery delay.

Odyssey Health is publicly traded on the OTC markets and pursues its concussion drug development activities as a development-stage biopharmaceutical company focused on advancing TM6 toward human clinical trials and ultimately FDA approval. According to odysseyhealth.com, the company's management team brings pharmaceutical development, regulatory affairs, and clinical research experience that supports the systematic advancement of TM6 through the preclinical and clinical development milestones required to bring the first pharmacological concussion treatment to patients. Odyssey Health's combination of novel concussion pharmacology approach, large unmet medical need target, clinical development focus, OTC-listed public company structure, and mission to develop the first approved drug treatment for mild traumatic brain injury reflects its positioning as an innovative development-stage company pursuing a genuinely important pharmacological advance in the field of brain trauma medicine.